May 15, 2014 • Volume 20 • Number 10

Clinical Cancer Research
Table of Contents

May 15, 2014 • Volume 20 • Number 10

Clinical Cancer Research
Table of Contents

May 15, 2014 • Volume 20 • Number 10

Clinical Cancer Research
Table of Contents

May 15, 2014 • Volume 20 • Number 10

Clinical Cancer Research
Table of Contents

May 15, 2014 • Volume 20 • Number 10

Clinical Cancer Research
Table of Contents

May 15, 2014 • Volume 20 • Number 10

Clinical Cancer Research
Table of Contents

May 15, 2014 • Volume 20 • Number 10

Clinical Cancer Research
Table of Contents

May 15, 2014 • Volume 20 • Number 10

Clinical Cancer Research
Table of Contents

May 15, 2014 • Volume 20 • Number 10

Clinical Cancer Research
Table of Contents

May 15, 2014 • Volume 20 • Number 10

Clinical Cancer Research
Table of Contents

Highlights of This Issue 2503

SPECIAL FEATURES

CCR Translations

2505  Minimal Residual Disease in Breast Cancer: In Blood Veritas
Giulia Siravegna and Alberto Bardelli
See related article, p. 2643

2506  Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer
Alastair M. Thompson

2507  Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer
Gary L. Johnson, Timothy J. Stuhlmiller, Steven P. Angus, Jon S. Zawistowski, and Lee M. Graves

2508  Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer
Alastair M. Thompson

2509  In Vivo Imaging as a Pharmacodynamic Marker
Astrid A.M. van der Veldt and Adriaan A. Lammertsma

2510  Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations
Robert Kinders, Kate Ferry-Galow, Lihua Wang, Apurva K. Senavastava, Jiuping (Jay) Ji, and Ralph E. Parchment

2511  Pharmacodynamic Biomarkers: Falling Short of the Mark?
Justin F. Gainor, Dan L. Longo, and Bruce A. Chabner

HUMAN CANCER BIOLOGY

2595  FOXM1 Promotes the Warburg Effect and Pancreatic Cancer Progression via Transactivation of LDHA Expression
Jiujie Cui, Min Shi, Dacheng Xie, Daoyan Wei, Zhiliang Jia, Shaojiang Zheng, Yong Gao, Suyun Huang, and Keping Xie

2596  Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
Edmund K. Bartlett, Patricia A. Fetsch, Armando C. Filie, Andrea Abati, Seth M. Steinberg, John R. Wunderlich, Donald E. White, Daniel J. Stephens, Francesco M. Marincola, Steven A. Rosenberg, and Udi S. Kammula

2597  miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression
Xuan Yu Chen, Xuangang Wang, Anming Ruan, Weiwei Han, Yan Zhao, Xing Lu, Pei Xiao, Hangchuan Shi, Rong Wang, Li Chen, Shaoyong Chen, Quansheng Du, Hongmei Yang, and Xiaoping Zhang

2598  Regulation of Colorectal Carcinoma Stemness, Growth, and Metastasis by an miR-200c–Sox2−Negative Feedback Loop Mechanism
Yan-Xia Lu, Li Yuan, Xiao-Lei Xue, Min Zhou, Yan Liu, Chao Zhang, Jing-Ping Li, Lin Zheng, Min Hong, and Xue-Nong Li
Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer
See related article, p. 2505

Id1-Induced IGF-II and Its Autocrine/Endocrine Promotion of Esophageal Cancer Progression and Chemoresistance—Implications for IGF-II and IGF-IR–Targeted Therapy
Bin Li, Sai Wah Tsao, Kwok Wah Chan, Dale L. Ludwig, Ruslan Novosyadlyy, Yuk Yin Li, Qing Yu He, and Annie L.M. Cheung

COX-2–Independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis
Anne-Sophie Gallouet, Marion Travers, Laurence Bresson-Bepoldin, Fabien Guillot, Céline Pangu, Sylvie Caula-Maugendre, Thierry Lamy, Karin Tarte, and Thierry Guillaudeux

Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo
Yansheng Hao, Bjorn Chapuy, Stefano Monti, Heather H. Sun, Scott J. Rodig, and Margaret A. Shipp

Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
Smita K. Nair, Gabriel De Leon, David Boczkowski, Robert Schmittling, WeiHua Xie, Jane Staats, Rebecca Liu, Laura A. Johnson, Kent Weinhold, Gary E. Archer, John H. Sampson, and Duane A. Mitchell

Anti-VEGF Antibodies Mitigate the Development of Radiation Necrosis in Mouse Brain

ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy
Fan Lin, Mark C. de Gooijer, Eloy Moreno Roig, Levi C.M. Buil, Susan M. Christner, Jan H. Beumer, Thomas Würdinger, Jos H. Beijnen, and Olaf van Tellingen

Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal
Li Li, Rui Han, Hualiang Xiao, Caifu Lin, Yubo Wang, Hao Liu, Kumin Li, Hengyi Chen, Fenfen Sun, Zhenzhou Yang, Jianxin Jiang, and Yong He

Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner
Diane Palmieri, Renata Duchiowska, Stephanie Wotsitska, Emily Hua, Yongzhen Qian, Wojciech Biernat, Katarzyna Soniska-Mielcarek, Brunilde Gril, Andreas M. Stark, Stephen M. Hewitt, David J. Liewehr, Seth M. Steinberg, Jacek Jassem, and Patricia S. Steeg

Biologic Effects of Platelet-Derived Growth Factor Receptor β Blockade in Uterine Cancer
Ju-Won Roh, Jie Huang, Wei Hu, XiaoYun Yang, Nicholas B. Jennings, Vasudha Sehgal, Bo Hwa Sohn, Hee Dong Han, Sun Joo Lee, Duangmani Thanapprapar, Justin Bottsford-Miller, Behrouz Zand, Heather J. Dalton, Rebecca A. Previs, Ashley N. Davis, Koji Matsuo, Ju-Seog Lee, Prablad Ram, Robert L. Coleman, and Anil K. Sood

Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume
Andrea G. Rockall, Norbert Aprill, Raymond Lam, Robert Iannone, P. David Mozley, Christine Parkinson, Donald Bergstrom, Evis Sala, Shah-Jalal Sarker, Iain A. McNeish, and James D. Brenton
### Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2761</td>
<td>A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response</td>
<td>Rita A. Busuttil, Joshy George, Richard W. Tothill, Kylie Ioculano, Adam Kowalczyk, Catherine Mitchell, Stephen Lade, Patrick Tan, Izhak Haviv, and Alex Boussioutas</td>
</tr>
<tr>
<td>2773</td>
<td>In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas</td>
<td>Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai, and David L. Rimm</td>
</tr>
<tr>
<td>2793</td>
<td>A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases</td>
<td>Josep Tabernero, Maria Elena Elez, Maria Herranz, Isabel Rico, Ludmila Prudkin, Jordi Andreu, Jose Mateos, Maria Josep Carreras, May Han, James Gifford, Marc Credi, Wei Yin, Shefali Agarwal, Philip Komarnitsky, and Jose Baselga</td>
</tr>
<tr>
<td>2805</td>
<td>Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff</td>
<td>Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Mojgan Haddad, Agnes Paquet, Yolanda Lie, Jodi M. Weidler, Weidong Huang, John Winslow, Tomasz Jankowski, Bogumila Czartoryska-Arghikovicz, Piotr J. Wysocki, Malgorzata Foszczyńska-Kłoda, Barbara Radecka, Maria M. Litwinijuk, Jolanta Żok, Michał Wiśniewski, Dorota Zuziak, Wojciech Biernat, and Jacek Jassem</td>
</tr>
</tbody>
</table>

**AC icon indicates Author Choice**

**CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org**

For more information please visit www.aacrjournals.org

### ABOUT THE COVER

The cover shows a brain section from a mouse injected with a brain seeking variant of the human breast cancer cell line MDA-MB-231. Immunohistochemical staining indicates a lack of MGMT expression in the tumor cells. Tissue was stained with anti-MGMT antibody and counterstained with hematoxylin and eosin. For details, see the article by Palmieri and colleagues on page 2727 of this issue.
Clinical Cancer Research

20 (10)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/10

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.